Project being implemented to reduce liver disease in Mongolia
The Government of Mongolia is working to reduce dramatically the number of Mongolians diagnosed with liver disease as well as bringing down the number of people infected with the hepatitis C virus.
Project is being implemented to reduce liver disease in Mongolia. The Government of Mongolia is working to reduce dramatically the number of Mongolians diagnosed with liver disease as well as bringing down the number of people infected with the hepatitis C virus, said Mongolian Prime Minister J.Erdenebat during his meeting with Ben Kamarck, Asia Pacific Regional Director of U.S. pharmaceuticals manufacturer Gilead Sciences. The sides discussed the cooperation in fighting hepatitis in Mongolia. Prime Minister also noted that Cabinet agreed to support the initiative for treatment program for the hepatitis patients between the ages of 45 to 60 in central Arkhangai Province. Mr. Kamarck emphasized that Harvoni has been shown to have a 98 percent success rate in the treatment of hepatitis C, and it is one the most expensive hepatitis C medications on the market. The government’s program to fight hepatitis will have a great impact on public health, and that Gilead Sciences will successfully implement the program in Arkhangai Province noted Mr. Kamarch. Gilead Sciences is implementing a project to reduce liver disease in Mongolia, and is providing 3,000 Mongolian patients with the hepatitis C medication Harvoni at a lower cost. The Ministry of Health has organized the distribution of Gilead Sciences medication to 1,000 patients receiving free medical services so far.
Views: 1018
Tweet